Drugs / Precision Cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02862587 | Aug 2016 → Mar 2018 | lung cancer | Shanghai International Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT02873442 | Aug 2016 → Mar 2018 | liver cancer | Ningbo Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02862613 | Aug 2016 → Mar 2018 | liver cancer | Shanghai International Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT02862561 | Aug 2016 → Mar 2018 | cancer | Shanghai International Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Precision Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02862613 ↗ |
| Modality | Cell therapy | “Objectives: To evaluate the safety and effectiveness of cell therapy using Precision Cells Combined With TACE in Advanced Liver Cancer.” NCT02862613 ↗ |
| Route | Subcutaneous | “subcutaneous injection for each infusion” NCT02862613 ↗ |